Impact of CYP3A and ABCB1 polymorphisms on the pharmacokinetics and pharmacodynamics of fentanyl

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 12, 2013, Pages 991-992

  Ziesenitz, Victoria C ^a,b   Van Den Anker, John N ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; FENTANYL; MULTIDRUG RESISTANCE PROTEIN 1;

DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; PHARMACODYNAMICS; PHARMACOGENETICS; RESPIRATION DEPRESSION; UNSPECIFIED SIDE EFFECT;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP3A; FEMALE; FENTANYL; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; P-GLYCOPROTEIN; PAIN, POSTOPERATIVE; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 84891340634     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201987     Document Type: Letter

References (7)

1. Kim KM, Kim HS, Lim SH, Cheong SH, Choi EJ, Kang H, Choi HR, Jeon JW, Yon JH, Oh M, Shin JG. Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients. Int J Clin Pharmacol Ther. 2013; 51: 383-392. PubMed
2. Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther. 2007; 81: 539-546. CrossRef PubMed
3. Tan PC, Hassan SK, Mohamad NA, Gan SH. Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl requirements. J Clin Pharm Ther. 2012; 37: 100-104. CrossRef PubMed
4. Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet. 2012; 27: 414-421. CrossRef PubMed
5. Eap CB, Buclin T, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, Telenti A, Kerb R. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol. 2004; 60: 231-236. CrossRef PubMed
6. Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res. 2005; 11: 7398-7404. CrossRef PubMed
7. Lee SJ, Lee SS, Jeong HE, Shon JH, Ryu JY, Sunwoo YE, Liu KH, Kang W, Park YJ, Shin CM, Shin JG. The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals. Drug Metab Dispos. 2007; 35: 2095-2101. CrossRef PubMed